Mediaspace scheduled maintenance: Aug 25, 2026 07:00 - 12:00 AM. During this time, videos will be temporarily unavailable. Check status updates.

Home

Person

Xiaomeng Hu

This person has left EPFL

About
Privacy
Disclaimer

Graph Chatbot

Related publications (5)

Page 1 of 1

IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases

Li Tang, Yi Wang, Yugang Guo, Bing Feng, Yang Zhao, Yuqing Xie, Xiaomeng Hu, Min Gao

The success of chimeric antigen receptor (CAR) T cell therapy in treating several hematopoietic malignancies has been difficult to replicate in solid tumors, in part because of T cell exhaustion and eventually dysfunction. To counter T cell dysfunction in ...

Nature Portfolio2024

Delivery approaches of immunomodulatory nucleic acids for cancer therapy

Li Tang, Xiaomeng Hu, Tom Enbar

Messenger RNA (mRNA) vaccines have made remarkable public health contributions during the pandemic and initiated a new era for nucleic acid–based therapeutics. With the unique strength of nucleic acids, including not only mRNA but also DNA, microRNA, small ...

2024

A Manganese Phosphate Nanocluster Activates the cGAS‐STING Pathway for Enhanced Cancer Immunotherapy

Li Tang, Yugang Guo, Armand Kurum, Kewen Lei, Yuqing Xie, Min Gao, Yu Zhao, Xiaomeng Hu

Targeting the stimulator of interferon genes (STING) pathway with cyclic dinucleotides (CDNs), the natural STING agonists, is a promising immunotherapeutic strategy for cancer. However, the clinical application of natural CDNs as therapeutics is greatly hi ...

2021

Nanotechnology enabled modulation of T cell immunity for cancer treatment

Xiaomeng Hu

Recent breakthroughs in cancer immunotherapy, exemplified by immune checkpoint blockade and CAR T cell therapy, have achieved remarkable clinical success. However, the majority of cancer patients fail to respond to immunotherapy or suffer from relapse. Nan ...

EPFL2023

Redox-Responsive Polycondensate Neoepitope for Enhanced Personalized Cancer Vaccine

Li Tang, Lixia Wei, Yu Zhao, Xiaomeng Hu

A versatile and highly effective platform remains a major challenge in the development of personalized cancer vaccines. Here, we devised a redox-responsive polycondensate neoepitope (PNE) through a reversible polycondensation reaction of peptide neoantigen ...

2020